Rosuvastatin
Rosuvastatin has been studied in 180 papers since 2007: 38 trials and 52 observational studies in people, 29 in animals, 8 in cells, 32 reviews; 111 in the past year. It is an approved medicine. The newest paper, Nov 18, 2026: “Effect of High-Intensity Statin Therapy on Coronary Plaque Composition Assessed by Machine Learning-Based Optical Coherence Tomography Analysis”.
InterventionStatinsApproved 2003
180 papers study it21 more mention it169 findingsUpdated
36 new papers in 30 daysSee all 200 papers on rosuvastatin
At a glance
A human trial reports less cognitive impairment with low-dose rosuvastatin versus placebo, and independent labs report reduced inflammation in humans; apoptosis results differ across cells and animals. Some registered trials concern aging; across all uses, most ended over a year ago without posted results or linked papers. Some trials are developer-sponsored, and some authors work at AstraZeneca.
169 findings in 81 papers from 2007 to 2026, 17 of them since April 2026
Independent labs found the same change in cells, mice and people. 65 independent labs in 23 countries; 492 trials, 88 about aging, 283 with no results posted.
“-0.54 (95% CI -1.88 to 0.80) for rosuvastatin compared with placebo”
6 of its findings point the other way.
- 65 independent labs in 23 countries
- 6 findings against
- 492 trials, 88 about aging, 283 with no results posted
- Funders: National Natural Science Foundation of China and others
- 4 of 164 findings with company ties
- 125 of 492 trials sponsored by its developers
- Human trial38
- Humans52
- Animals29
- Cells8
- In silico3
Studies in people
See all 20 studies of rosuvastatin in people20 studies gave rosuvastatin to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases endocan down: Decreases endoglin | Treated cohortmedian 12 (IQR 8–12) weeks | 128 peoplewomenmedian age 60 years (IQR 56–64 years)Postmenopausal women aged up to 70 years | Biomedicines, Aug 27, 2026 |
no change: Has no effect on psoriasis area and severity indexChange from baseline: -2.34 (SD 2.81) versus -1.93 (SD 3.33); P = 0.38 no change: Has no effect on dermatology life quality index | Trial12 weeks | 24 peoplePlaque psoriasis with cardiovascular risk; add-on versus standard therapy | Perspectives in clinical research, Jan 17, 2026 |
down: Decreases cardiac biomarkers up: Improves global left ventricular strain down: Lowers the risk of atrial fibrillation8% versus 24%; p = 0.001 | Trial8, 24, and 48 hours after surgery | Chronic statin users undergoing off-pump coronary artery bypass grafting; loading versus no loading | Cureus, Jan 12, 2026 |
up: Improves LDL-C target attainment rate81.1% vs. 67.6%, p = 0.02 | Trial16 weeks | 145 peopleWomenPostmenopausal women | Biomedicines, Jan 6, 2026 |
| Randomized trial8 weeks | 105 people≥60 yearsSTEMI patients aged ≥60 years | Frontiers in cardiovascular medicine, Aug 22, 2025 |
What did studies of rosuvastatin find?
97Studies of rosuvastatin measured 97 outcomes, among them inflammation, apoptosis and mortality.
Inflammation
downin humans3downin mice1downin O. cuniculus1downin rats1
6 studies
Inflammation
downin humans3downin mice1downin O. cuniculus1downin rats1
Rosuvastatin decreases inflammation in humans.
“After treatment, serum levels of hs-CRP, IL-6, TNF-α, and ICAM-1 decreased in both groups (P < 0.05), with the reductions being more pronounced in the intensive group compared to the control group (P < 0.05).”
Human trial8 weeksn = 105
Frontiers in cardiovascular medicine
Rosuvastatin decreases inflammation in humans (STEMI undergoing PCI) (P < 0.05).
“intensive group showed significantly reduced serum inflammatory levels compared to the control group, including C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and intercellular adhesion molecule-1”
Human trialSTEMI undergoing PCIheart20 mg/day vs 10 mg/day8 weeksn = 100
Frontiers in cardiovascular medicine
Rosuvastatin decreases inflammation in humans (coronary heart disease).
“lower levels of hs-CRP, TNF-α, BNP and NT-proBNP were observed in the observation group than in the control group at T3 and T4 (P<0.05).”
Human trialcoronary heart disease20 daysn = 100
American journal of translational research
Rosuvastatin decreases inflammation in humans (unstable angina pectoris).
“hs-CRP and IL-6 levels decreased in both groups after treatment and were lower in group B than in group A (P<0.05).”
Human trialunstable angina pectorisoral10 mg/day vs 5 mg/dayn = 106
American journal of translational research
Rosuvastatin decreases inflammation in rats (burn wound) (P < 0.01).
“Histopathology revealed a statistically significant reduction in inflammatory infiltration, coagulative necrosis, and microhemorrhage (P < 0.01).”
Animalsburn woundcreamskinmalesn = 90
Experimental beneficial effect of rosuvastatin on burn wound healing in a rat model
World journal of experimental medicine
Rosuvastatin decreases inflammation in mice (sepsis).
“it ameliorated lung inflammation”
Animalssepsislung
The beneficial effects of Rosuvastatin in inhibiting inflammation in sepsis
Aging
Rosuvastatin decreases inflammation in O. cuniculus (compared with fluvastatin, under high-cholesterol diet) (greater reduction than fluvastatin).
“Nevertheless, rosuvastatin administration resulted in a greater reduction in MYD88, NF-kB, chemokines”
Animalscompared with fluvastatin, under high-cholesterol dietmyocardium
Journal of clinical medicine
Apoptosis
downin rats2downin cells1upin human cells1upin mice1+1
6 studies
Apoptosis
downin rats2downin cells1upin human cells1upin mice1+1
Rosuvastatin decreases apoptosis in cells (ox-LDL-induced).
“rosuvastatin protected against ox-LDL-induced endothelial apoptosis”
Cellsox-LDL-inducedendothelial cells
PloS one
Rosuvastatin induces apoptosis in mice (adulthood).
“an increased ovarian follicular atresia, as confirmed by increased cleaved caspase-9 and caspase-3 immunostaining in the granulosa cells of antral follicles, in the rosuvastatin-treated females”
Animalsadulthoodgavageovaryfemales
Toxicology letters
Rosuvastatin induces apoptosis in lipopolysaccharide-stimulated HT-29 and Caco-2 cells.
“Both pathways converge upon activation of executioner caspase-3 and an increase in Annexin V-defined apoptotic fractions”
Cellsin lipopolysaccharide-stimulated HT-29 and Caco-2 cells
International journal of molecular sciences
Rosuvastatin decreases apoptosis in rat cells (mechanical stretch; cultures from hypertensive rats).
“Rosuvastatin can reduce vascular remodeling and allostatic overload during hypertension by decreasing MS-associated apoptosis/fibrosis in mesenteric VSMC”
Cellsmechanical stretch; cultures from hypertensive ratsmesenteric vascular smooth muscle cell10−5 mol/L
Current hypertension reviews
Rosuvastatin decreases apoptosis in rats after gamma irradiation.
“the suppression of intrinsic apoptosis triggered by radiation, as shown by decreased cleaved caspase-3 expression”
Animalsafter gamma irradiationkidney10 mg/kg i.p.
Naunyn-Schmiedeberg's archives of pharmacology
Rosuvastatin decreases apoptosis in spontaneously hypertensive rats.
“Rosuvastatin can inhibit myocardial apoptosis in hypertensive rats through up-regulating SIRT1 and down-regulating NF-κB.”
Animalsin spontaneously hypertensive ratsmyocardium
Cellular and molecular biology (Noisy-le-Grand, France)
Mortality
no changein humans2downin humans1downin mice1HR 0.96
4 studies
Mortality
no changein humans2downin humans1downin mice1HR 0.96
Rosuvastatin showed no clear effect on mortality in humans (elective operations under general anesthesia) (6.1% vs 8.7%, OR = 0.67, 95%CI: 0.39-1.2, P = 0.147).
“No significant difference in 30-d all-cause mortality (6.1% vs 8.7%, OR = 0.67, 95%CI: 0.39-1.2, P = 0.147) was observed between the two groups.”
Human trialelective operations under general anesthesia40 mg/d30-dn = 821
World journal of clinical cases
Rosuvastatin decreases mortality in humans (hypertension) (all p < 0.05).
“cardiovascular death, and all-cause death were significantly lower in the rosuvastatin group than the placebo group (all p < 0.05).”
Human trialhypertension83.5 monthsn = 1,244
Frontiers in cardiovascular medicine
Rosuvastatin was not clearly linked with mortality in humans (primary biliary cholangitis) (HR, 0.960 [95% CI, 0.710–1.296]; p = 0.788).
“High-intensity hydrophilic and high-intensity lipophilic statins did not differ in all-cause mortality (HR, 0.960 [95% CI, 0.710–1.296]; p = 0.788)”
Humansprimary biliary cholangitis≥ 20 mg5-year
BMC gastroenterology
Rosuvastatin decreases mortality in mice (sepsis).
“the administration of Rosuvastatin reduced the mortality of sepsis mice”
Animalssepsis
The beneficial effects of Rosuvastatin in inhibiting inflammation in sepsis
Aging
LDL cholesterol
downin humans3
3 studies
LDL cholesterol
downin humans3
Rosuvastatin decreases LDL cholesterol in humans.
“After 6 weeks of using high-dose rosuvastatin, the levels of total cholesterol and LDL were significantly decreased (P value = 0.001).”
Human trial6 weeksn = 110
BMC cardiovascular disorders
Rosuvastatin decreases LDL cholesterol in humans (acute coronary syndrome) (72.6 ± 17.5 to 50.9 ± 18.9, p = 0.001).
“there was a significant reduction in total cholesterol (136.2 ± 24.3 to 115.5 ± 24.0, p = 0.001) and LDL levels”
Human trialacute coronary syndrome40 mg6 weeksn = 110
BMC cardiovascular disorders
Rosuvastatin decreases LDL cholesterol in humans (coronary heart disease).
“the observation group obtained lower TC and LDL-C levels than the control group at T3 and T4 (P<0.05).”
Human trialcoronary heart disease20 daysn = 100
American journal of translational research
Rosuvastatin decreases LDL cholesterol in humans (Highest-ranked regimen for LDL cholesterol reduction in the network meta-analysis) (P-score 0.9906).
“For LDL-C reduction, rosuvastatin 10 mg ranked highest (P-score 0.9906)”
ReviewHighest-ranked regimen for LDL cholesterol reduction in the network meta-analysis10 mg
AHA Scientific Sessions 2026 abstract
HDL cholesterol
upin humans3
3 studies
HDL cholesterol
upin humans3
Rosuvastatin increases HDL cholesterol in humans (38.3 ± 7.1 to 47.2 ± 7.4).
“Also, the level of HDL was 38.3 ± 7.1 before treatment and remarkably increased to 47.2 ± 7.4 after treatment (P value = 0.001).”
Human trial6 weeksn = 110
BMC cardiovascular disorders
Rosuvastatin increases HDL cholesterol in humans (acute coronary syndrome) (38.3 ± 7.1 to 47.2 ± 7.4, p = 0.001).
“accompanied by a notable increase in HDL levels (38.3 ± 7.1 to 47.2 ± 7.4, p = 0.001)”
Human trialacute coronary syndrome40 mg6 weeksn = 110
BMC cardiovascular disorders
Rosuvastatin increases HDL cholesterol in humans (compared with atorvastatin, with exercise) (+12 ± 9 mg/dL (+30%) vs +5 ± 5 mg/dL (+13%), p=0.014).
“Rosuvastatin significantly increased HDL-C (rosuvastatin, +12 ± 9 mg/dL [+30%], atorvastatin, +5 ± 5 mg/dL [+13%], p=0.014)”
Human trialcompared with atorvastatin, with exercise20 weeks
Atherosclerosis
Rosuvastatin increases HDL cholesterol in humans (Acute coronary syndrome; compared with atorvastatin) (WMD -1.15; 95% CI -1.99 to -0.32).
“rosuvastatin may provide greater short-term reductions in CRP and modest increases in HDL-C compared with atorvastatin”
ReviewAcute coronary syndrome; compared with atorvastatin≤1 month
Cardiology in review
C-reactive protein
downin humans3
3 studies
C-reactive protein
downin humans3
Rosuvastatin decreases C-reactive protein in humans (Compared with atorvastatin after excluding one outlying study) (MD −0.16 mg/L; 95% CI −0.28 to −0.03; p = 0.01).
“rosuvastatin demonstrated a greater CRP reduction (MD –0.16 mg/L; 95% CI –0.28 to –0.03; p = 0.01)”
ReviewCompared with atorvastatin after excluding one outlying study
AHA Scientific Sessions 2026 abstract
Rosuvastatin decreases C-reactive protein in humans (Acute coronary syndrome; compared with atorvastatin) (WMD 4.08; 95% CI 1.53–6.63).
“rosuvastatin may provide greater short-term reductions in CRP and modest increases in HDL-C compared with atorvastatin”
ReviewAcute coronary syndrome; compared with atorvastatin≤1 month
Cardiology in review
Rosuvastatin decreases C-reactive protein in humans after excluding one outlier (MD: -0.16 mg/L).
“rosuvastatin showed a greater reduction (MD: - 0.16 mg/L; 95% CI: - 0.28 to - 0.03; p = 0.01; I2 = 63%).”
Reviewafter excluding one outliern = 6,148
BMC cardiovascular disorders
SIRT1
upin rats2upin humans1
3 studies
SIRT1
upin rats2upin humans1
Rosuvastatin increases SIRT1 in humans.
“Quantitative gene expression analysis showed that SIRT1 significantly upregulated in patients with MS after 3 months of statin therapy (P < 0.001) (see panel A of the ).”
Human trial3 monthsn = 25
Current therapeutic research, clinical and experimental
Rosuvastatin activates SIRT1 in rats after gamma irradiation.
“ROSU activated SIRT1 and promoted FOXO3a deacetylation”
Animalsafter gamma irradiationkidney10 mg/kg i.p.
Naunyn-Schmiedeberg's archives of pharmacology
Rosuvastatin increases SIRT1 in rats (compared with the SHR group).
“while the expression levels of Bcl-2 and SIRT1 were remarkably lower than those in the Rosuvastatin group (p<0.05)”
Animalscompared with the SHR groupmyocardium
Cellular and molecular biology (Noisy-le-Grand, France)
Extracellular matrix remodeling
downin cells1downin humans1
2 studies
Extracellular matrix remodeling
downin cells1downin humans1
Rosuvastatin inhibits extracellular matrix remodeling in humans.
“Post-treatment comparisons between groups showed that the intensive group had significantly lower levels of NT-proBNP, Galectin-3, and MMP-9 compared to the control group (P < 0.05), and significantly higher TIMP-4 levels (P < 0.05).”
Human trial8 weeksn = 105
Frontiers in cardiovascular medicine
Rosuvastatin inhibits extracellular matrix remodeling in humans (STEMI undergoing PCI) (P < 0.05).
“Markers of ventricular remodeling also improved in the intensive group, with lower levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), galectin-3, and matrix metalloproteinase-9 (MMP-9)”
Human trialSTEMI undergoing PCIheart20 mg/day vs 10 mg/day8 weeksn = 100
Frontiers in cardiovascular medicine
Rosuvastatin inhibits extracellular matrix remodeling in response to TNF-α stimulation.
“In vitro experiments demonstrate that rosuvastatin promotes matrix anabolism and suppresses catabolism in response to TNF-α stimulation.”
Cellsin response to TNF-α stimulation
Acta biochimica et biophysica Sinica
IL-6
no changein humans1downin rats1
2 studies
IL-6
no changein humans1downin rats1
Rosuvastatin showed no clear effect on IL-6 in humans (head-to-head comparison with atorvastatin) (MD: -0.82).
“We observed no significant differences for IL-6 (n = 484; MD: - 0.82; 95% CI: - 3.02 to 1.38)”
Reviewhead-to-head comparison with atorvastatinn = 484
BMC cardiovascular disorders
Rosuvastatin decreases IL-6 in rats (rats fed high-fat diet, valve cusps implanted subcutaneously).
“Statin treatment significantly attenuated bioprosthetic heart valve calcification associated with decreasing the levels of interleukin-6 and bone morphogenetic protein 2.”
Animalsrats fed high-fat diet, valve cusps implanted subcutaneouslybioprosthetic valve cuspn = 20
Rosuvastatin attenuates bioprosthetic heart valve calcification
The Journal of thoracic and cardiovascular surgery
Cellular senescence
downin cells2
2 studies
Cellular senescence
downin cells2
Rosuvastatin decreases cellular senescence in bone marrow-derived macrophages.
“Restoring lipid homeostasis with rosuvastatin enhanced lipophagy, recovered ABCA1/ABCG1-mediated cholesterol export, attenuated macrophage senescence and inflammatory activation and improved efferocytosis.”
Cellsin bone marrow-derived macrophages
Macrophage Lipid Homeostasis Drives IVDD via a Senescence-Dependent Impairment of Efferocytosis
Cell proliferation
Rosuvastatin inhibits cellular senescence in cells (induced by TNF-α).
“In addition, rosuvastatin inhibits cell pyroptosis and senescence induced by TNF-α.”
Cellsinduced by TNF-α
Acta biochimica et biophysica Sinica
Adverse reactions
downin humans1no changein humans1
2 studies
Adverse reactions
downin humans1no changein humans1
Rosuvastatin showed no clear effect on adverse reactions in humans (unstable angina pectoris).
“No statistical difference was observed in the incidence of adverse reactions between the two groups after treatment (P>0.05).”
Human trialunstable angina pectorisoral10 mg/day vs 5 mg/dayn = 106
American journal of translational research
Rosuvastatin is linked with lower adverse reactions in humans.
“The incidence of adverse reactions such as loss of appetite, headache, dizziness, fatigue, constipation, etc. in patients in the rosuvastatin group was lower than that in the atorvastatin group, p < 0.05.”
Humanscompared with atorvastatin in elderly patients with coronary artery disease and hyperlipidemian = 216
Open life sciences
Left ventricular ejection fraction
upin humans2
2 studies
Left ventricular ejection fraction
upin humans2
Rosuvastatin increases left ventricular ejection fraction in humans.
“Intergroup comparisons after treatment revealed that the intensive group had significantly lower LVESD and LVESV values (P < 0.05), and significantly higher LVEF and stroke volume compared to the control group (P < 0.05).”
Human trial8 weeksn = 105
Frontiers in cardiovascular medicine
Rosuvastatin improves left ventricular ejection fraction in humans (coronary heart disease).
“After treatment, the observation group scored higher in the LVEF level and lower in the WMSI score than the control group (both P<0.05).”
Human trialcoronary heart disease20 daysn = 100
American journal of translational research
Hospitalization time
downin humans2
2 studies
Hospitalization time
downin humans2
Rosuvastatin decreases hospitalization time in humans (elective operations under general anesthesia) (13.8 ± 2.5 vs 14.2 ± 2.8, P = 0.03).
“Rosuvastatin decreased the hospitalization time (13.8 ± 2.5 vs 14.2 ± 2.8, P = 0.03) and hospitalization expenses (9.3 ± 2.5 vs 9.8 ± 2.9, P = 0.007).”
Human trialelective operations under general anesthesia40 mg/dn = 821
World journal of clinical cases
Rosuvastatin decreases hospitalization time in humans (elective general anesthesia operation) (13.8±2.5 vs 14.2±2.8 days, P=0.03).
“Rosuvastatin can decrease the hospitalization time (13.8±2.5 vs 14.2±2.8, P=0.03) and hospitalization expenses (9.3±2.5 vs 9.8±2.9, P=0.007).”
Human trialelective general anesthesia operation40 mg/day
Research SquarePreprint
Endoglin
downin humans1
1 study
Endoglin
downin humans1
Rosuvastatin decreases endoglin in postmenopausal women with dyslipidemia.
“statistically significant decreases in the plasma concentrations of the endothelial dysfunction markers endocan and endoglin were recorded in both the atorvastatin (Wilcoxon test, p < 0.001) and rosuvastatin (Wilcoxon test, p < 0.001) groups”
Human trialin postmenopausal women with dyslipidemiamedian 12 (IQR 8–12) weeksn = 64
Biomedicines
Rosuvastatin is linked with lower endoglin in humans (primary cardiovascular prevention).
“Atorvastatin and rosuvastatin therapies significantly decreased plasma concentrations of both endocan and endoglin”
Humansprimary cardiovascular preventionplasmaup to 16 weeksfemales
Biomedicines
Endocan
downin humans1
1 study
Endocan
downin humans1
Rosuvastatin decreases endocan in postmenopausal women with dyslipidemia.
“statistically significant decreases in the plasma concentrations of the endothelial dysfunction markers endocan and endoglin were recorded in both the atorvastatin (Wilcoxon test, p < 0.001) and rosuvastatin (Wilcoxon test, p < 0.001) groups”
Human trialin postmenopausal women with dyslipidemiamedian 12 (IQR 8–12) weeksn = 64
Biomedicines
Rosuvastatin is linked with lower endocan in humans (primary cardiovascular prevention).
“Atorvastatin and rosuvastatin therapies significantly decreased plasma concentrations of both endocan and endoglin”
Humansprimary cardiovascular preventionplasmaup to 16 weeksfemales
Biomedicines
All 97Fewer
What is rosuvastatin linked with?
26Studies link rosuvastatin with 26 measures, among them major adverse cardiovascular events, rhabdomyolysis and dementia.
Major adverse cardiovascular events
upin humans1downin humans1RR 1.21
2 studies
Major adverse cardiovascular events
upin humans1downin humans1RR 1.21
Rosuvastatin is associated with major adverse cardiovascular events in humans (ACS and multivessel coronary disease; compared with atorvastatin) (RR 1.21, 95% CI 0.79–1.85; P = 0.372).
“rosuvastatin versus atorvastatin had an RR of 1.21 (95% CI, 0.79–1.85; P = 0.372)”
HumansACS and multivessel coronary disease; compared with atorvastatin3 monthsn = 277
PloS one
Rosuvastatin is associated with major adverse cardiovascular events in humans (HR 0.84, 95% CI 0.76–0.93; 624 versus 769 events).
“rosuvastatin was associated with a lower major adverse cardiovascular events rate than atorvastatin (624 versus 769 events; hazard ratio [HR], 0.84 [95% CI, 0.76-0.93]).”
HumansPatients with cancer receiving tyrosine kinase inhibitors; comparison with atorvastatin; time-averaged association because proportional hazards were violatedDay 30 to up to 3 years
Journal of the American Heart Association
Rhabdomyolysis
upin humans2
2 studies
Rhabdomyolysis
upin humans2
Rosuvastatin is associated with rhabdomyolysis in humans (polypharmacy; adverse reaction classified as probable).
“We present a probable case of rosuvastatin-associated rhabdomyolysis causing stage 3 acute kidney injury requiring hemodialysis in an 87-year-old woman with polypharmacy”
Humanspolypharmacy; adverse reaction classified as probable20 mg/day20 daysfemales
The American journal of case reports
Rosuvastatin is associated with rhabdomyolysis in humans During concomitant ticagrelor therapy after percutaneous coronary intervention.
“We present a case of severe rhabdomyolysis and AKI following initiation of high-intensity rosuvastatin therapy after percutaneous coronary intervention.”
HumansDuring concomitant ticagrelor therapy after percutaneous coronary intervention40 mg once dailyOne monthfemales
Cureus
Dementia
downin humans2HR 0.82
2 studies
Dementia
downin humans2HR 0.82
Rosuvastatin lowers the risk of dementia in APOE ε4 allele carriers.
“Rosuvastatin medication significantly alleviated the cognitive impairment progression and the risks of dementia in patients with APOE ε4 allele.”
Human trialin APOE ε4 allele carriers
Frontiers in aging neuroscience
Rosuvastatin is linked with a lower risk of dementia in humans (propensity-matched comparison with non-users) (adjusted HR 0.82 (95% CI 0.78-0.87)).
“Among seven commonly prescribed statins, rosuvastatin was associated with the greatest preventive effect on dementia incidence, with an adjusted HR of 0.82 (95% CI = 0.78-0.87).”
Humanspropensity-matched comparison with non-usersn = 264,036
Impact of Statin Use on Dementia Incidence in Elderly Men and Women with Ischemic Heart Disease
Biomedicines
Minimum fibrous-cap thickness
upin humans1
1 study
Minimum fibrous-cap thickness
upin humans1
Rosuvastatin is associated with minimum fibrous-cap thickness in humans (ST-segment elevation myocardial infarction) (93.98 to 117.26 μm).
“Minimum fibrous-cap thickness increased from 93.98 to 117.26 μm (p = 0.027)”
HumansST-segment elevation myocardial infarctionnonculprit coronary vesselshigh-intensityn = 33
The American journal of cardiology
Vascular dementia
downin humans1HR 0.7
1 study
Vascular dementia
downin humans1HR 0.7
Rosuvastatin is associated with vascular dementia in humans (type 2 diabetes; compared with atorvastatin users) (HR 0.70, 95% CI 0.65–0.76; incidence 0.4% vs 0.6%; ARD -0.20%, 95% CI -0.23 to -0.16).
“rosuvastatin use was associated with significantly lower risks of incident dementia including Alzheimer dementia, and vascular dementia compared with atorvastatin.”
Humanstype 2 diabetes; compared with atorvastatin users
Comparative Dementia Outcomes of Rosuvastatin and Atorvastatin in Adults with Type 2 Diabetes
AHA Scientific Sessions 2026 abstract
Alzheimer's disease
downin humans1HR 0.78
1 study
Alzheimer's disease
downin humans1HR 0.78
Rosuvastatin is associated with Alzheimer's disease in humans (type 2 diabetes; compared with atorvastatin users) (HR 0.78, 95% CI 0.72–0.83; incidence 0.5% vs 0.6%; ARD -0.18%, 95% CI -0.22 to -0.15).
“Rosuvastatin use was also associated with lower risks of Alzheimer dementia”
Humanstype 2 diabetes; compared with atorvastatin users
Comparative Dementia Outcomes of Rosuvastatin and Atorvastatin in Adults with Type 2 Diabetes
AHA Scientific Sessions 2026 abstract
Incident dementia
downin humans1HR 0.77
1 study
Incident dementia
downin humans1HR 0.77
Rosuvastatin is associated with incident dementia in humans (type 2 diabetes; compared with atorvastatin users) (HR 0.77, 95% CI 0.74–0.80; incidence 1.6% vs 2.2%; ARD -0.65%, 95% CI -0.72 to -0.58).
“Compared with atorvastatin users, rosuvastatin users had a lower incidence of dementia”
Humanstype 2 diabetes; compared with atorvastatin users
Comparative Dementia Outcomes of Rosuvastatin and Atorvastatin in Adults with Type 2 Diabetes
AHA Scientific Sessions 2026 abstract
Hyperglycemic event reporting
upin humans1
1 study
Hyperglycemic event reporting
upin humans1
Rosuvastatin is associated with hyperglycemic event reporting in humans (FAERS pharmacovigilance analysis in patients without diabetes) (Reporting odds ratio 2.44; 95% CI 2.31–2.58).
“rosuvastatin (ROR: 2.44; 95% CI: 2.31-2.58)”
HumansFAERS pharmacovigilance analysis in patients without diabetes
Frontiers in pharmacology
Acute kidney injury
upin humans1
1 study
Acute kidney injury
upin humans1
Rosuvastatin is associated with acute kidney injury in humans During concomitant ticagrelor therapy after percutaneous coronary intervention.
“We present a case of severe rhabdomyolysis and AKI following initiation of high-intensity rosuvastatin therapy after percutaneous coronary intervention.”
HumansDuring concomitant ticagrelor therapy after percutaneous coronary interventionkidney40 mg once dailyOne monthfemales
Cureus
Type 2 diabetes
upin humans1HR 1.07
1 study
Type 2 diabetes
upin humans1HR 1.07
Rosuvastatin is linked with a higher risk of type 2 diabetes in patients with established ASCVD on moderate-intensity statin therapy (adjusted HR 1.07, 95% CI 1.01-1.14).
“rosuvastatin (adjusted HR 1.07, 95% CI 1.01-1.14), pravastatin (HR 1.19, 95% CI 1.02-1.38), and simvastatin (HR 1.15, 95% CI 1.06-1.20) were associated with higher NODM risk compared with atorvastatin”
Humansin patients with established ASCVD on moderate-intensity statin therapy
Frontiers in cardiovascular medicine
Atrial fibrillation
downin humans1
1 study
Atrial fibrillation
downin humans1
Rosuvastatin lowers the risk of atrial fibrillation in humans (8% versus 24%; p = 0.001).
“Postoperative atrial fibrillation (AF) occurred less frequently in the loaded group (8% versus 24%, p = 0.001).”
Human trialPostoperative incidence in chronic statin users undergoing off-pump coronary artery bypass grafting; loading versus no loading40 mg once
Cureus
Falls
downin humans1HR 0.532
1 study
Falls
downin humans1HR 0.532
Rosuvastatin lowers the risk of falls in humans (hypertensive patients) (HR 0.532, 95% CI 0.408-0.694).
“0.532 (95% CI 0.408-0.694), respectively, in the rosuvastatin group compared with placebo group.”
Human trialhypertensive patientsaverage 72 monthsn = 943
Hypertension research : official journal of the Japanese Society of Hypertension
Balance impairment
downin humans1HR 0.542
1 study
Balance impairment
downin humans1HR 0.542
Rosuvastatin lowers the risk of balance impairment in humans (hypertensive patients) (HR 0.542, 95% CI 0.442-0.663).
“The hazard ratio of incident balance impairment and falls was 0.542 [95% confidence interval (CI) 0.442-0.663] and 0.532 (95% CI 0.408-0.694), respectively, in the rosuvastatin group”
Human trialhypertensive patientsaverage 72 monthsn = 943
Hypertension research : official journal of the Japanese Society of Hypertension
Delirium
downin humans1OR 0.522
1 study
Delirium
downin humans1OR 0.522
Rosuvastatin lowers the risk of delirium in humans (elective operations under general anesthesia) (OR = 0.522, 95% CI: 0.308-0.885; P < 0.05).
“The incidence of postoperative delirium was significantly lower in the rosuvastatin group [23 (5.6%) of 410 patients] than in the placebo group”
Human trialelective operations under general anesthesia40 mg/dn = 821
World journal of clinical cases
Cardiovascular disease
downin humans1
1 study
Cardiovascular disease
downin humans1
Rosuvastatin lowers the risk of cardiovascular disease in humans (hypertension) (all p < 0.05).
“The risks of composite cardiovascular event, myocardial infarction, coronary revascularization, heart failure, total stroke, ischemic stroke, cardiovascular death, and all-cause death were significantly lower in the rosuvastatin group”
Human trialhypertension83.5 monthsn = 1,244
Frontiers in cardiovascular medicine
All 26Fewer
What acts on rosuvastatin?
1Studies name beta-lactams as acting on rosuvastatin.
Beta-lactams
downin humans1
1 study
Beta-lactams
downin humans1
Beta-lactams are linked with rosuvastatin in humans (patients with CHD on statin therapy).
“concomitant β-lactam use impairs rosuvastatin efficacy in patients with CHD”
Humanspatients with CHD on statin therapy
Journal of cardiovascular pharmacology
Has rosuvastatin been tested in people?
88 of 492 about agingYes: 38 trials and 52 observational studies in people have been published, and 480 trials are registered.
About aging
The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study
Phase 3Completed
A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)
Phase 3Completed
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events
Phase 3Terminated
PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis
Phase 3Recruiting
C-Reactive Protein (CRP) in Obese Diabetic Women
Phase 4Completed
Phase 3Completed
All 40Fewer
Approved
Aug 12, 2003Atherosclerosis, Homozygous Familial Hypercholesterolemia, Hypercholesterolemia, Hypertriglyceridemia, Primary Hypercholesterolemia, dysbetalipoproteinemia, heterozygous familial hypercholesterolemia
Dec 18, 2018Discontinued
Repurposing
Phase 4Completed10 trials
Phase 4Results posted12 trials
Phase 4Completed32 trials
Phase 4Completed2 trials
Phase 4Results posted13 trials
Phase 4Results posted14 trials
40 of 128Fewer
Every condition in trials
Hyperlipidemias
Phase 4Results posted34 trials
Hyperlipoproteinemia type II
Phase 4Results posted4 trials
Coronary Artery Disease Progression
Phase 4Completed2 trials
Prostatic neoplasm
Phase 4Completed2 trials
Hyperlipoproteinemia type IV
Phase 4Results posted1 trial
Hyperlipoproteinemia type V
Phase 4Results posted1 trial
All 34Fewer
Readouts due
- Nov 22, 2026
- Dec 5, 2026
Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants
Phase 1Active, not recruiting
- Dec 31, 2026
A Phase I Study of the Interaction of D-2570 With Other Drugs in Healthy Adults
Phase 1Not yet recruiting
- Jan 25, 2027
Phase 1Active, not recruiting
- Feb 9, 2027
A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants (MK-6916-012)
Phase 1Not yet recruiting
- Mar 2027
A Study of LY4515100 in Healthy Participants
Phase 1Recruiting
All 14Fewer
Stopped
NCT00651378TerminatedHypercholesterolemia
Slow enrollment \[HIGH SCREEN FAILURE RATE\]
NCT00673582TerminatedAtherosclerosis
Sponsor has withdrawn the funding
NCT02105623TerminatedCoronary artery disease
Slow enrollement, Low Follow-up rate
NCT02740699TerminatedCardiovascular disease
Principal Investigator resigned and closed program
NCT01975194TerminatedStroke
loss of research personnel
NCT02968160TerminatedMetabolic syndrome
Due to poor enrollment rate
All 13Fewer
Who is developing rosuvastatin?
3 companies: Organon, Merck Sharp & Dohme and AstraZeneca.
Trial sponsors
Company70 trialsPhase 476,164 people
Company14 trialsPhase 41,259 people
Company12 trialsPhase 4929 people
Company4 trialsPhase 4583 people
Company2 trialsPhase 480 people
Company1 trialPhase 4300 people
Company1 trialPhase 4223 people
Company1 trialPhase 448 people
Funding
1 grant since 2026São Paulo Research Foundation
How this record changed
Summary rewritten as its findings changed.
As it read before
A human study reports lower plasma endoglin and endocan with rosuvastatin in women receiving primary cardiovascular prevention for up to 16 weeks. A review reports reduced C-reactive protein after outlier exclusion, but no TNF-alpha or IL-6 difference versus atorvastatin.
Summary written from the findings.